Background: Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition that predisposes patients to severe complications when infected with SARS-CoV-2 (COVID-19). Hematological alterations, particularly in erythrocyte levels, may influence the clinical course and outcomes in these high-risk individuals. Objective: This study aimed to evaluate the erythrocyte profile of COPD patients with and without COVID-19 at RS Paru Dr. Ario Wirawan Salatiga. Methods: An analytic study design was employed. Participants were recruited using consecutive sampling. All COPD patients admitted between March 2019 and December 2023 were included. A total of 53 COPD patients participated, comprising 27 COVID-19-positive and 26 COVID-19-negative patients. Results: The mean erythrocyte level in the COVID-19-positive COPD group was 4.23 ± 0.73 million/µl, while in the COVID-19-negative COPD group, it was 4.77 ± 0.78 million/µl. Although a statistically significant difference was observed between the two groups (p = 0.012), both values remain within the normal reference range. Conclusion: Erythrocyte levels in both the COVID-19-positive and COVID-19-negative COPD groups remained within the normal range, although the levels were relatively lower in the COVID-19-positive group with statistical significance. Further research is needed to explore the underlying mechanisms contributing to this difference.
No takes yet. Share an insight, caveat, or question.
Chasanah et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: